ABSTRACT Objective: To evaluate the cost-utility of latanoprostene bunod 0.024% as first-line therapy compared to the strategy recommended by the Clinical Protocol and Therapeutic Guidelines for primary open-angle glaucoma of the Brazilian Unified Health System. Methods: A cost-utility analysis was conducted using a hypothetical cohort and a Markov model. In the base-case scenario, the treatment strategy recommended by the Clinical Protocol and Therapeutic Guidelines was adopted, initiating therapy with timolol 0.5%. If the target intraocular pressure was not achieved, dorzolamide […]
